Skip to main content
Top
Published in: BMC Infectious Diseases 1/2023

Open Access 01-12-2023 | Obesity | Research

Major risk factors for Streptococcus dysgalactiae subsp. equisimilis bacteremia: a population-based study

Authors: Viivi Nevanlinna, Reetta Huttunen, Janne Aittoniemi, Tiina Luukkaala, Sari Rantala

Published in: BMC Infectious Diseases | Issue 1/2023

Login to get access

Abstract

Background

Streptococcus dysgalactiae subspecies equisimilis is a human pathogen causing severe invasive infections. Detailed information on S. dysgalactiae subsp. equisimilis bacteremia and especially of predisposing factors are lacking. The purpose of the study is to investigate the risk factors of S. dysgalactiae subsp. equisimilis bacteremia compared to the general population in Finland.

Methods

We retrospectively reviewed all patients older than 18 years with S. dysgalactiae subsp. equisimilis bacteremia in the Pirkanmaa health district from August 2015 to July 2018. The risk factors for S. dysgalactiae subsp. equisimilis bacteremia were investigated with respect to the normal population in Finland using the Finhealth study data provided by the Finnish institute for health and welfare. The study group was matched with the Finhealth study by age and sex.

Results

Altogether 230 cases of S. dysgalactiae subsp. equisimilis bacteremia were detected. The medical records of 217 episodes of S. dysgalactiae subsp. equisimilis bacteremia (involving 211 patients) were available for analysis. Obesity was a statistically significant risk factor for S. dysgalactiae subsp. equisimilis bacteremia (Odds Ratio 2.96 [95% CI 2.22–3.96]). Diabetes and coronary artery disease were also associated with an increased risk of S. dysgalactiae subsp. equisimilis bacteremia (OR 4.82 [95% CI 3.62–6.42]) and (OR 3.03 [95% CI 2.18–4.19]).

Conclusions

We found obesity, diabetes, and coronary artery disease to be associated with an increased risk for S. dysgalactiae subsp. equisimilis bacteremia. These results provide an increased understanding of risk factors for S. dysgalactiae subsp. equisimilis bacteremia.
Literature
1.
go back to reference Facklam R. What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin Microbiol Rev. 2002;15:613–30.CrossRef Facklam R. What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin Microbiol Rev. 2002;15:613–30.CrossRef
3.
go back to reference Ekelund K, Skinhøj P, Madsen J, Konradsen HB. Invasive group A, B, C and G Streptococcal infections in Denmark 1999–2002: Epidemiological and clinical aspects. Clin Microbiol Infect. 2005;11:569–76.CrossRef Ekelund K, Skinhøj P, Madsen J, Konradsen HB. Invasive group A, B, C and G Streptococcal infections in Denmark 1999–2002: Epidemiological and clinical aspects. Clin Microbiol Infect. 2005;11:569–76.CrossRef
4.
go back to reference Rantala S, Vuopio-Varkila J, Vuento R, Huhtala H, Syrjänen J. Clinical presentations and epidemiology of β-haemolytic streptococcal bacteraemia: a population-based study. Clin Microbiol Infect. 2009;15:286–8.CrossRef Rantala S, Vuopio-Varkila J, Vuento R, Huhtala H, Syrjänen J. Clinical presentations and epidemiology of β-haemolytic streptococcal bacteraemia: a population-based study. Clin Microbiol Infect. 2009;15:286–8.CrossRef
5.
go back to reference Lambertsen LM, et al. Nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011. Clin Microbiol Infect. 2014;20:O216.CrossRef Lambertsen LM, et al. Nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011. Clin Microbiol Infect. 2014;20:O216.CrossRef
6.
go back to reference Schwartz IS, Keynan Y, Gilmour MW, Dufault B, Lagacé-Wiens P. Changing trends in β-hemolytic streptococcal bacteremia in Manitoba, Canada: 2007–2012. Int J Infect Dis. 2014;28:211–3.CrossRef Schwartz IS, Keynan Y, Gilmour MW, Dufault B, Lagacé-Wiens P. Changing trends in β-hemolytic streptococcal bacteremia in Manitoba, Canada: 2007–2012. Int J Infect Dis. 2014;28:211–3.CrossRef
7.
go back to reference Sylvetsky N, Raveh D, Schlesinger Y, Rudensky B, Yinnon AM. Bacteremia due to beta-hemolytic Streptococcus group G: increasing incidence and clinical characteristics of patients. Am J Med. 2002;112:622–6.CrossRef Sylvetsky N, Raveh D, Schlesinger Y, Rudensky B, Yinnon AM. Bacteremia due to beta-hemolytic Streptococcus group G: increasing incidence and clinical characteristics of patients. Am J Med. 2002;112:622–6.CrossRef
9.
go back to reference Lother SA, et al. Clonal clusters and virulence factors of Group C and G streptococcus causing severe infections, Manitoba, Canada, 2012–2014. Emerg Infect Dis. 2017;23:1092–101.CrossRef Lother SA, et al. Clonal clusters and virulence factors of Group C and G streptococcus causing severe infections, Manitoba, Canada, 2012–2014. Emerg Infect Dis. 2017;23:1092–101.CrossRef
10.
go back to reference Rantala S. Streptococcus dysgalactiae subsp. equisimilis bacteremia: an emerging infection. Eur J Clin Microbiol Infect Dis. 2014;33:1303–10.CrossRef Rantala S. Streptococcus dysgalactiae subsp. equisimilis bacteremia: an emerging infection. Eur J Clin Microbiol Infect Dis. 2014;33:1303–10.CrossRef
11.
go back to reference Cohen-Poradosu R, et al. Group G streptococcal bacteremia in Jerusalem. Emerg Infect Dis. 2004;10:1455–60.CrossRef Cohen-Poradosu R, et al. Group G streptococcal bacteremia in Jerusalem. Emerg Infect Dis. 2004;10:1455–60.CrossRef
13.
go back to reference Harris P, Siew DA, Proud M, Buettner P, Norton R. Bacteraemia caused by beta-haemolytic streptococci in North Queensland: changing trends over a 14-year period. Clin Microbiol Infect. 2011;17:1216–22.CrossRef Harris P, Siew DA, Proud M, Buettner P, Norton R. Bacteraemia caused by beta-haemolytic streptococci in North Queensland: changing trends over a 14-year period. Clin Microbiol Infect. 2011;17:1216–22.CrossRef
14.
go back to reference Rantala S, Vuopio-Varkila J, Vuento R, Huhtala H, Syrjänen J. Predictors of mortality in beta-hemolytic streptococcal bacteremia: a population-based study. J Infect. 2009;58:266–72.CrossRef Rantala S, Vuopio-Varkila J, Vuento R, Huhtala H, Syrjänen J. Predictors of mortality in beta-hemolytic streptococcal bacteremia: a population-based study. J Infect. 2009;58:266–72.CrossRef
15.
go back to reference Rantala S, Vähäkuopus S, Vuopio-Varkila J, Vuento R, Syrjänen J. Streptococcus dysgalactiae subsp. equisimilis Bacteremia, Finland, 1995–2004. Emerg Infect Dis. 2010;16:843–6.CrossRef Rantala S, Vähäkuopus S, Vuopio-Varkila J, Vuento R, Syrjänen J. Streptococcus dysgalactiae subsp. equisimilis Bacteremia, Finland, 1995–2004. Emerg Infect Dis. 2010;16:843–6.CrossRef
16.
go back to reference Kaspersen KA, et al. Obesity and risk of infection: results from the Danish blood donor study. Epidemiology. 2015;26:580–9.CrossRef Kaspersen KA, et al. Obesity and risk of infection: results from the Danish blood donor study. Epidemiology. 2015;26:580–9.CrossRef
19.
go back to reference Wang HE, Griffin R, Judd S, Shapiro NI, Safford MM. Obesity and risk of sepsis: a population-based cohort study. Obesity. 2013;21:E762–9.CrossRef Wang HE, Griffin R, Judd S, Shapiro NI, Safford MM. Obesity and risk of sepsis: a population-based cohort study. Obesity. 2013;21:E762–9.CrossRef
20.
go back to reference Langley G, et al. The impact of obesity and diabetes on the risk of disease and death due to invasive group a streptococcus infections in adults. Clin Infect Dis. 2016;62:845–52.CrossRef Langley G, et al. The impact of obesity and diabetes on the risk of disease and death due to invasive group a streptococcus infections in adults. Clin Infect Dis. 2016;62:845–52.CrossRef
26.
go back to reference Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. Int J Obes. 2013;37:333–40.CrossRef Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. Int J Obes. 2013;37:333–40.CrossRef
28.
go back to reference Michalia M, et al. Diabetes mellitus is an independent risk factor for ICU-acquired bloodstream infections. Intensive Care Med. 2009;35:448–54.CrossRef Michalia M, et al. Diabetes mellitus is an independent risk factor for ICU-acquired bloodstream infections. Intensive Care Med. 2009;35:448–54.CrossRef
29.
go back to reference Factor SH, et al. Invasive group a streptococcal disease: risk factors for adults. Emerg Infect Dis. 2003;9:970.CrossRef Factor SH, et al. Invasive group a streptococcal disease: risk factors for adults. Emerg Infect Dis. 2003;9:970.CrossRef
30.
go back to reference Ogura K, Okumura K, Shimizu Y, Kirikae T, Miyoshi-Akiyama T. Pathogenicity induced by invasive infection of Streptococcus dysgalactiae subsp. equisimilis in a mouse model of diabetes. Front Microbiol. 2018;9:2128.CrossRef Ogura K, Okumura K, Shimizu Y, Kirikae T, Miyoshi-Akiyama T. Pathogenicity induced by invasive infection of Streptococcus dysgalactiae subsp. equisimilis in a mouse model of diabetes. Front Microbiol. 2018;9:2128.CrossRef
34.
go back to reference Wajima T, et al. Molecular characterization of invasive Streptococcus dysgalactiae subsp. Equisimilis, Japan. Emerg Infect Dis. 2016;22:247–54.CrossRef Wajima T, et al. Molecular characterization of invasive Streptococcus dysgalactiae subsp. Equisimilis, Japan. Emerg Infect Dis. 2016;22:247–54.CrossRef
Metadata
Title
Major risk factors for Streptococcus dysgalactiae subsp. equisimilis bacteremia: a population-based study
Authors
Viivi Nevanlinna
Reetta Huttunen
Janne Aittoniemi
Tiina Luukkaala
Sari Rantala
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-023-07992-9

Other articles of this Issue 1/2023

BMC Infectious Diseases 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine